Your browser is no longer supported. Please, upgrade your browser.
FATE [NASD]
Fate Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.85 Insider Own0.90% Shs Outstand86.89M Perf Week-2.34%
Market Cap9.99B Forward P/E- EPS next Y-1.80 Insider Trans-9.74% Shs Float85.69M Perf Month22.44%
Income-148.60M PEG- EPS next Q-0.39 Inst Own- Short Float15.27% Perf Quarter136.15%
Sales18.30M P/S545.79 EPS this Y-21.50% Inst Trans0.06% Short Ratio11.31 Perf Half Y230.20%
Book/sh4.88 P/B23.28 EPS next Y0.00% ROA-31.20% Target Price81.75 Perf Year367.54%
Cash/sh5.56 P/C20.43 EPS next 5Y- ROE-43.60% 52W Range16.75 - 121.16 Perf YTD24.92%
Dividend- P/FCF- EPS past 5Y-2.60% ROI-41.10% 52W High-6.25% Beta1.70
Dividend %- Quick Ratio9.20 Sales past 5Y- Gross Margin- 52W Low578.15% ATR7.72
Employees178 Current Ratio9.20 Sales Q/Q216.70% Oper. Margin- RSI (14)67.05 Volatility5.64% 6.66%
OptionableYes Debt/Eq0.00 EPS Q/Q-69.90% Profit Margin- Rel Volume0.70 Prev Close117.40
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume1.16M Price113.59
Recom1.70 SMA2012.98% SMA5046.06% SMA200151.00% Volume808,091 Change-3.25%
May-13-20Initiated H.C. Wainwright Buy $42
Mar-04-20Initiated Barclays Overweight $40
Jan-09-20Downgrade BMO Capital Markets Outperform → Market Perform $22
Dec-30-19Reiterated Mizuho Buy $27 → $33
Dec-09-19Upgrade Wells Fargo Market Perform → Outperform
Nov-12-19Initiated SunTrust Buy $25
Nov-06-19Downgrade Wells Fargo Outperform → Market Perform
Oct-01-19Initiated Stifel Buy $27
Aug-09-19Initiated BTIG Research Buy $27
Jul-22-19Initiated Cantor Fitzgerald Overweight
Jul-12-19Initiated Oppenheimer Outperform $27
Jun-13-19Initiated Mizuho Buy
Jun-07-19Initiated ROTH Capital Neutral $20
May-31-19Initiated Guggenheim Buy
May-24-19Resumed Citigroup Buy $26
Mar-28-19Initiated SVB Leerink Outperform $20
Jan-03-19Downgrade Stephens Overweight → Equal-Weight
Nov-05-18Initiated Jefferies Buy
Aug-01-18Initiated Citigroup Buy $20
Mar-06-18Downgrade H.C. Wainwright Buy → Neutral $12
Jan-11-21 08:02AM  
Jan-08-21 04:26PM  
09:01AM  
08:50AM  
Jan-07-21 04:24PM  
Jan-06-21 12:30AM  
Jan-05-21 06:23AM  
Jan-04-21 04:01PM  
Dec-30-20 10:42AM  
07:18AM  
Dec-29-20 09:37AM  
Dec-28-20 10:43AM  
Dec-23-20 09:21AM  
Dec-22-20 04:30PM  
Dec-09-20 08:42AM  
Dec-08-20 01:22PM  
Dec-07-20 04:20PM  
03:33PM  
12:39PM  
10:00AM  
Dec-06-20 10:05AM  
Dec-05-20 11:32AM  
Dec-04-20 04:01PM  
10:43AM  
Nov-30-20 08:00AM  
Nov-12-20 04:01PM  
Nov-10-20 05:54AM  
Nov-07-20 02:00AM  
Nov-05-20 06:05PM  
04:01PM  
03:45PM  
08:00AM  
Nov-03-20 09:15AM  
Nov-02-20 07:00AM  
Oct-15-20 08:00AM  
Sep-30-20 08:00AM  
Sep-11-20 10:11AM  
Sep-04-20 08:00AM  
Aug-19-20 08:00AM  
Aug-11-20 08:19AM  
08:00AM  
Aug-05-20 05:55PM  
04:01PM  
Aug-04-20 04:01PM  
Jul-29-20 04:01PM  
Jul-28-20 12:32PM  
Jul-26-20 07:40AM  
Jul-21-20 08:11AM  
Jul-16-20 11:06AM  
Jul-14-20 08:00AM  
Jul-10-20 10:18AM  
Jul-09-20 08:00AM  
Jun-15-20 10:50PM  
01:44PM  
Jun-13-20 07:50AM  
Jun-11-20 04:01PM  
Jun-09-20 05:29PM  
02:10PM  
12:49AM  
Jun-08-20 04:01PM  
May-20-20 08:00AM  
May-15-20 06:18AM  
May-12-20 04:30PM  
01:40PM  
May-11-20 05:15PM  
04:01PM  
May-08-20 08:46AM  
May-05-20 09:18PM  
04:01PM  
May-04-20 04:01PM  
09:38AM  
Apr-30-20 08:33AM  
Apr-29-20 07:11AM  
Apr-28-20 04:30PM  
12:33PM  
Apr-14-20 09:13AM  
Apr-10-20 12:00PM  
Apr-08-20 11:30AM  
10:05AM  
10:04AM  
Apr-06-20 09:08AM  
Apr-04-20 09:07AM  
Apr-03-20 06:34PM  
04:20PM  
10:57AM  
07:36AM  
Apr-02-20 04:46PM  
04:45PM  
Mar-25-20 09:04AM  
Mar-17-20 10:24AM  
Mar-02-20 05:15PM  
04:01PM  
Feb-29-20 02:52PM  
Feb-26-20 08:00AM  
Feb-25-20 12:30PM  
Feb-07-20 08:00AM  
Feb-05-20 11:52AM  
Jan-16-20 06:15AM  
Jan-13-20 08:00AM  
Jan-03-20 10:44AM  
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shoemaker Daniel DChief Scientific OfficerJan 11Sale110.813,253360,47783,609Jan 12 08:38 PM
TAHL CINDYGeneral Counsel and SecretaryJan 11Sale110.813,254360,58790,035Jan 12 08:39 PM
Valamehr BahramChief Development OfficerJan 11Sale110.813,254360,58877,727Jan 12 08:40 PM
Wolchko J ScottPresident and CEOJan 11Sale110.818,587951,556350,562Jan 12 08:41 PM
Redmile Group, LLCDirectorJan 08Buy85.50327,48527,999,96812,957,222Jan 12 04:16 PM
Wolchko J ScottPresident and CEOJan 08Sale117.1060,8207,122,217359,149Jan 12 08:41 PM
Valamehr BahramChief Development OfficerJan 08Sale117.106,230729,55280,981Jan 12 08:40 PM
TAHL CINDYGeneral Counsel and SecretaryJan 08Sale117.106,229729,43493,289Jan 12 08:39 PM
Shoemaker Daniel DChief Scientific OfficerJan 08Sale117.106,229729,43486,862Jan 12 08:38 PM
Wolchko J ScottPresident and CEODec 17Option Exercise6.6220,000132,400439,969Dec 18 04:01 PM
Wolchko J ScottPresident and CEODec 17Sale91.8220,0001,836,352419,969Dec 18 04:01 PM
Valamehr BahramChief Development OfficerDec 14Option Exercise2.9025,00072,500112,211Dec 15 04:01 PM
Valamehr BahramChief Development OfficerDec 14Sale97.7825,0002,444,47787,211Dec 15 04:01 PM
Shoemaker Daniel DChief Scientific OfficerNov 16Sale51.8325,0001,295,74693,091Nov 16 05:12 PM
Wolchko J ScottPresident and CEONov 13Option Exercise5.7330,000172,008430,123Nov 16 04:02 PM
Wolchko J ScottPresident and CEONov 13Sale51.0330,0001,530,900419,969Nov 16 04:02 PM
Wolchko J ScottPresident and CEONov 12Option Exercise2.7330,00081,900449,969Nov 16 04:02 PM
Wolchko J ScottPresident and CEONov 12Sale52.7230,0001,581,524419,969Nov 16 04:02 PM
TAHL CINDYGeneral Counsel and SecretaryNov 05Option Exercise2.8219,28254,340118,800Nov 06 04:02 PM
TAHL CINDYGeneral Counsel and SecretaryNov 05Sale50.6319,282976,25299,518Nov 06 04:02 PM
TAHL CINDYGeneral Counsel and SecretaryNov 04Option Exercise2.7351,519140,647151,037Nov 06 04:02 PM
TAHL CINDYGeneral Counsel and SecretaryNov 04Sale50.4151,5192,597,14099,518Nov 06 04:02 PM
TAHL CINDYGeneral Counsel and SecretaryOct 16Option Exercise2.7329,19979,713128,717Oct 20 04:01 PM
TAHL CINDYGeneral Counsel and SecretaryOct 16Sale50.2529,1991,467,21299,518Oct 20 04:01 PM
TAHL CINDYGeneral Counsel and SecretaryOct 01Option Exercise2.7335,00095,550134,518Oct 02 04:01 PM
TAHL CINDYGeneral Counsel and SecretaryOct 01Sale40.7435,0001,426,06599,518Oct 02 04:01 PM
Valamehr BahramChief Development OfficerSep 14Option Exercise2.7525,00068,778112,211Sep 16 04:02 PM
Shoemaker Daniel DChief Scientific OfficerSep 14Sale36.3025,000907,540118,091Sep 16 04:01 PM
Valamehr BahramChief Development OfficerSep 14Sale36.2825,000907,02487,211Sep 16 04:02 PM
Redmile Group, LLCDirectorJun 11Buy28.311,412,92839,999,99212,629,737Jun 17 08:25 PM
RASTETTER WILLIAM HDirectorMar 30Option Exercise1.3728,46138,99228,461Mar 31 04:01 PM
Valamehr BahramChief Development OfficerFeb 03Option Exercise1.691,1531,94987,211Feb 04 04:01 PM
Wolchko J ScottPresident and CEOJan 30Option Exercise2.7025,00067,500444,969Feb 03 04:01 PM
Wolchko J ScottPresident and CEOJan 30Sale25.4525,000636,303419,969Feb 03 04:01 PM